Two meta‐analyses showed that TP53 co‐mutation was a negative prognostic factor in lung cancer patients who were with EGFR mutations and were treated with targeted therapy, whereas there was no predictive value in patients who were treated with non‐targeted therapy.38, 39. This evidence concerns the gene TP53 and lung cancer.